CAR-T cell injection for advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new treatment called ACT#001 CAR-T cells, given as a local injection, for prostate cancer that has stopped responding to hormone therapy. It aims to see if this therapy is safe and can help shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- Your doctor expects you to live at least 3 more months.
- Your prostate cancer has not responded to hormone therapy, and you have had at least one new type of hormone treatment.
- You must have a PSMA-positive tumor (a specific marker on cancer cells).
- You need to be in fairly good health, with a performance score of 0 or 1 (able to do daily activities).
- You cannot have had certain prior treatments like other cell therapies or PSMA-targeted therapies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests whether lab-made immune cells (CAR-T) that target PSMA can treat prostate cancer that keeps growing despite hormone treatment. It may help people whose disease no longer responds to standard endocrine (hormone-blocking) therapy.
This trial tests a new immune cell therapy (CAR-NK cells) made from a healthy donor's cells. It is designed to attack prostate cancer that has spread and become resistant to hormone therapy, especially if your cancer cells have the PSMA protein.
This trial tests a new immunotherapy called A-CAR032, which uses your own immune cells to attack prostate cancer cells. It is for men with metastatic castration-resistant prostate cancer that has progressed after other treatments.
This Phase 1 study tests a type of immune cell treatment (CAR T) made to recognize PSMA, a marker on prostate cancer cells. It’s for advanced prostate cancer and aims to find a safe dose and how well the treatment works.
This Phase 1 study tests a new drug that aims to attach to PSMA on prostate cancer cells and activate T-cells (an immune cell type) to attack the cancer. It is for men with advanced prostate cancer that no longer responds to hormone therapy, especially after several prior treatments.
This trial tests a new type of immune cell therapy (CAR-NK cells) designed to target and fight advanced prostate cancer that has stopped responding to hormone treatments. The cells are engineered to recognize and attack cancer cells that have specific markers (PSMA and PSCA) on their surface.
Hear when a new Castration-Resistant Prostate Cancer (CRPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.